May 25, 2018 9:00 AM ET

Pharmaceuticals

Company Overview of Nabriva Therapeutics AG

Company Overview

Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The company’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical stu...

Leberstrasse 20

Vienna,  1110

Austria

Founded in 2005

Phone:

43 0 1 740 93 0

Fax:

43 0 1 740 93 1900

Key Executives for Nabriva Therapeutics AG

CEO & Member of Management Board
Age: 61
CFO & Principal Accounting Officer
Age: 55
Chief Medical Officer
Age: 52
Chief Development Officer
Age: 49
Chief Medical Officer
Compensation as of Fiscal Year 2017.

Nabriva Therapeutics AG Key Developments

Nabriva Therapeutics AG and Roivant Services Initiate Collaboration to Develop and Commercialize Lefamulin in Greater China

Nabriva Therapeutics AG and Roivant Services have initiated a collaboration to develop and commercialize lefamulin in greater China. Lefamulin has completed an international phase 3 clinical trial for the treatment of adults with moderate to severe community-acquired bacterial pneumonia (CABP). Topline data from a second international phase 3 clinical trial are expected in the spring of 2018. As part of the license agreement, Nabriva has granted a Roivant subsidiary an exclusive license to develop and commercialize lefamulin in China, Hong Kong, Macau and Taiwan. Nabriva will receive a $5 million upfront payment and will be eligible for up to approximately $90 million in additional payments tied to the successful completion of certain regulatory and commercial milestones related to lefamulin for CABP. In addition, Nabriva will be eligible to receive low double-digit royalties on sales upon approval in the covered territories. Roivant's affiliate will be solely responsible for all clinical development and regulatory filings necessary to secure approval in the covered territories.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nabriva Therapeutics AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.